Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 9c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.79, $0.09 better than the analyst estimate of $1.70. Revenue for the quarter came in at $119.2 million versus the consensus estimate of $122.3 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• NVIDIA (NVDA) 10K contracts of September 125 puts trade
• AMD (AMD) call put ratio 1 call to 1.8 put with a focus on August 28 weekly 305 puts